Oren Gilad - 10 Dec 2025 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role: President/CEO, Director
Signature: /s/ John P. Hamill, as Attorney-in-Fact
Issuer symbol: APRE
Transactions as of: 10 Dec 2025
Transactions value $: $25,000
Form type: 4
Filing time: 11 Dec 2025, 08:30:14 UTC
Previous filing: 04 Apr 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Gilad Oren	President/CEO, Director	3805 OLD EASTON ROAD, DOYLESTOWN	/s/ John P. Hamill, as Attorney-in-Fact	11 Dec 2025	0001929300

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	APRE	Common Stock						346K	10 Dec 2025	Direct
holding	APRE	Common Stock						1.2K	10 Dec 2025	By Daughter	F1
holding	APRE	Common Stock						600	10 Dec 2025	By Son	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APRE	Pre-Funded Warrant	Purchase	$25K	+21.5K		$1.17	21.5K	10 Dec 2025	Common Stock	21.5K	$0.00	Direct	F2, F3
transaction	APRE	Common Warrants	Purchase		+21.5K			21.5K	10 Dec 2025	Common Stock	21.5K	$1.04	Direct	F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
F2	On December 8, 2025, the Issuer entered into a securities purchase agreement with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement which closed on December 10, 2025 pre-funded warrants ("Pre-Funded Warrants") to purchase an aggregate of 21,459 shares of the Issuer's common stock ("Shares") at a purchase price of $1.165 per Pre-Funded Warrant. The Reporting Person also received accompanying common warrants ("Common Warrants") to purchase up to an aggregate of 21,459 Shares.
F3	The Pre-Funded Warrants are immediately exercisable at any time after the date of issuance. Pursuant to the terms of the Pre-Funded Warrants, the Pre-Funded Warrants cannot be exercised to the extent that, upon giving effect to or immediately prior to such exercise, would cause either (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) would exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise or (ii) the combined voting power of the Issuer's securities beneficially owned by such holder (together with its affiliates) would exceed 9.99% of the combined voting power of all of the Issuer's securities outstanding immediately after giving effect to the exercise (the "Beneficial Ownership Limitation")
F4	The Common Warrants are immediately exercisable, subject to the Beneficial Ownership Limitation. The Common Warrants will expire on or prior to 5:00 p.m. (New York City time) on the fifth year anniversary of the earlier of: (i) the effective date of the registration statement registering the underlying Shares of the Common Warrants and (ii) the date the Shares underlying the Common Warrants are eligible for sale under Rule 144 (assuming cashless exercise of the Common Warrants) without the requirement for the Issuer to be in compliance with the current public information required under Rule 144.